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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumours with a
typical 5 year survival rate of <40 %. DNA methylation in tumour-suppressor genes often occurs at an early stage of
tumorigenesis, hence DNA methylation can be used as an early tumour biomarker. Saliva is an ideal diagnostic
medium to detect early HNSCC tumour activities due to its proximity to tumour site, non-invasiveness and ease of
sampling. We test the hypothesis that the surveillance of DNA methylation in five tumour-suppressor genes
(RASSF1α, p16INK4a, TIMP3, PCQAP/MED15) will allow us to diagnose HNSCC patients from a normal healthy control
group as well as to discriminate between Human Papillomavirus (HPV)-positive and HPV-negative patients.
Methods: Methylation-specific PCR (MSP) was used to determine the methylation levels of RASSF1α, p16INK4a, TIMP3
and PCQAP/MED15 in DNA isolated from saliva. Statistical analysis was carried out using non-parametric Mann-
Whitney’s U-test for individually methylated genes. A logistic regression analysis was carried out to determine the
assay sensitivity when combing the five genes. Further, a five-fold cross-validation with a bootstrap procedure was
carried out to determine how well the panel will perform in a real clinical scenario.
Results: Salivary DNA methylation levels were not affected by age. Salivary DNA methylation levels for RASSF1α,
p16INK4a, TIMP3 and PCQAP/MED15 were higher in HPV-negative HNSCC patients (n = 88) compared with a normal
healthy control group (n = 122) (sensitivity of 71 % and specificity of 80 %). Conversely, DNA methylation levels for
these genes were lower in HPV-positive HNSCC patients (n = 45) compared with a normal healthy control group
(sensitivity of 80 % and specificity of 74 %), consistent with the proposed aetiology of HPV-positive HNSCCs.
Conclusions: Salivary DNA tumour-suppressor methylation gene panel has the potential to detect early-stage
tumours in HPV-negative HNSCC patients. HPV infection was found to deregulate the methylation levels in HPV-
positive HNSCC patients. Large-scale double-blinded clinical trials are crucial before this panel can potentially be
integrated into a clinical setting.
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Background
Head and neck squamous cell carcinomas (HNSCCs)
encompasses tumours within the oral cavity, pharynx,
larynx, paranasal sinuses, nasal cavity and salivary
glands, and are some of the most aggressive cancer types
[1, 2]. Main risk factors for HNSCC include smoking, al-
cohol consumption, betel quid chewing, and Human
Papillomavirus (HPV, mainly HPV-16 and HPV-18) in-
fections [2–4]. HPV-positive and HPV-negative cancers
are biologically and clinically different and as such re-
quire different treatment and clinical management [5].
HNSCC is the sixth most common cancer worldwide
with ~780,000 new cases diagnosed each year [6]. The
incidence of HNSCC in developed countries has de-
creased over the past 20 years, which is largely attributed
to a reduction in smoking and alcohol consumption [4].
However, the incidence of HPV-positive HNSCC is on
the rise and accounts for 30 to 50 % of all HNSCCs [4,
6]. HPV-positive HNSCC patients have cancers that are
almost exclusively located in the oropharynx [7–10].
HPV-positive HNSCC patients are often young with a
higher socioeconomic status and typically non-smokers
[7–10]. The five-year survival rates for HPV-negative
HNSCC when diagnosed early is 80 % compared with
only 15 % for the advanced stage cancers [11–13].
Currently, diagnosis relies on the direct examination
of the head and neck regions and is usually made after
clinical presentation of symptoms and involves biopsy to
confirm diagnosis. The HPV status of a patient is deter-
mined by p16INK4a immunohistochemistry (IHC) stain-
ing on tumour tissue samples and histological
classification using the tumour-node-metastasis (TNM)
[14–16]. Direct examination is highly-subjective and be-
comes problematic when tumours are too small to be
visualised, or are hidden in obscure areas such as the
tonsillar crypts or within the pits and crevices in the lin-
gual tonsils of the tongue base. This would then likely
require techniques such as nasendoscopy or examination
under anaesthesia to locate the tumour and both require
biopsy for confirmation. These issues may commonly re-
sult in misdiagnosis [17]. The direct contact between sal-
iva and oral cavity lesions make the measurement of the
tumour markers in saliva an attractive alternative to
serum and tumour tissue biopsy testings [6, 18–21]. Sal-
iva is now championed as the diagnostic fluid of the fu-
ture over blood and urine as saliva testing is easy,
inexpensive, safe, and non-invasive [19, 22–25].
Gene-specific DNA methylation, especially in tumour-
suppressor genes, is recognized as a contributor to the
regulation of gene expression and phenotypic heterogen-
eity in HNSCC [26, 27]. The DNA promoter methyla-
tion analysis in saliva samples collected from HNSCC
patients have previously been shown to demonstrate
clinical utility [6, 25, 28]. The most commonly used
method for the detection of DNA methylation analysis
in tissue and body fluids is the methylation-specific
PCRs (MSPs) [29]. MSP analysis is highly sensitive and
does not require expensive laboratory equipment and is
therefore economical compared to other quantitative
DNA methylation analysis such as pyrosequencing and
real-time quantitate MSP [30, 31]. In addition, MSP is
able to provide a time-efficient and direct DNA methyla-
tion status analysis, making it convenient for large-scale
sample screening [30, 31]. The ability to relatively quan-
tify DNA methylation signatures allows the delineation
of clinically meaningful threshold values to discriminate
a patient cohort from a control cohort.
We hypothesise that by analysing DNA methylation of
tumour-suppressor genes in saliva; we can detect early
tumour activities as well as to differentially diagnose
HNSCC patients. Our study objectives are two-fold: (i)
firstly, to investigate the early diagnostic potential of the
salivary DNA methylation panel (RASSF1α, p16INK4a,
TIMP3, PCQAP 5′ and PCQAP 3′) (ii) secondly, to de-
termine whether this panel is able to discriminate be-
tween HPV-negative and HPV-positive HNSCC patients.
We selected this panel as we have previously published
individual DNA methylation levels in saliva collected
from HNSCC patient and controls except for TIMP3.
From our previously published work, we were able to
discriminate normal healthy controls from HNSCC
patients using these individual DNA methylation levels
[6, 25]. In this study, we have combined the DNA
methylation levels for all of the five tumour-suppressor
genes as a panel to increase the sensitivity and specificity
when discriminating normal healthy controls from
HNSCC patients. Our salivary DNA methylation panel
is able to detect HPV-negative HNSCC patients from a
normal healthy control group with a sensitivity of 71 %
and specificity of 80 %. In contrast, the DNA methyla-
tion levels were lower in saliva collected from HPV-
positive HNSCC patients compared with normal healthy
controls (sensitivity of 80 % and specificity of 74 %). It is
important to conduct a multi-centre clinical trial before
this panel can be implemented in a clinical setting.
Methods
Study design
This study is approved by the University of Queens-
land (HREC no.: 2014000679) and Queensland Uni-
versity of Technology (HREC no.: 1400000617)
Medical Ethical Institutional Boards and the Princess
Alexandra Hospital’s (PAH) Ethics Review Board
(HREC no.: HREC/12/QPAH/381). We have re-
cruited normal healthy controls, both smokers and
non-smokers (n = 122) and HNSCC patients (n =
133). HNSCC patient cohort consisted of HPV-
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negative and HPV-positive patients. The Table 1 pre-
sents the demographic and clinical characteristics of
our study cohort.
Determination of HPV-16 status in tumour samples
We obtained a pathology report for each patient which
contained tumour staging information, histopathological
grading and HPV-16 status. HPV-16 status was deter-
mined by staining for p16INK4a in tumour tissue section
using IHC (CINtec® Histology Kit, Roche MTM Labora-
tories, Heidelberg, Germany) according to the manufac-
turer’s protocol [32]. p16 INK4a IHC was evaluated by
trained pathologists [32]. The determination of HPV-16
status at the PAH is restricted to patients with cancers
in the oropharynx because of the low prevalence of
HPV-16 among non-oropharynx sites [9]. Therefore,
p16INK4a IHC is not requested by the treating clinician
when tumours are outside of the oropharyngeal area.
Saliva sample collection and processing
In the clinic, volunteers were asked to refrain from eat-
ing and drinking for an hour prior to donating saliva
samples. The volunteers were asked to sit in a comfort-
able position and were asked to rinse their mouths with
water to remove food debris. They were then asked to
pool saliva in the mouth and expectorate directly into a
50 mL Falcon tube. Saliva samples were transported
from the hospital to the laboratory on dry ice. Samples
were centrifuged at 1500 × g for 10 min at 4 °C, separat-
ing cellular pellet from cell-free salivary supernatant.
Cellular pellet was used to isolate DNA, which was sub-
sequently subjected to bisulfite conversion.
DNA extraction and bisulfite conversion from saliva
samples
The Epitect® Plus DNA Bisulfite Kit (Cat. No. 59124,
Qiagen, Duesseldorf, Germany) was used to extract and
bisulfite-convert DNA from salivary cellular pellet accord-
ing to the manufacturer’s protocol. An additional 10 min
of incubation time was adapted due to a change in elution
volume of 17 μL instead of 15 μL. Purity and quantity of
the converted DNA samples were measured with a Nano
Drop ND-1000 spectrophotometer (Thermo Fisher
Scientific, Waltham, Massachusetts, USA).
Table 1 The demographic characteristics of the study cohort
(n = 255)
Explanatory
variables
Controls Patients
HPV -ve HPV + ve
n = 122 (47.8 %) n = 88 (34.5 %) n = 45 (17.7 %)
Demographics
Gender
Male 54 (44.3) 67 (76.1) 42 (93.3)
Female 68 (55.7) 21 (23.9) 3 (6.7)
Age
< 50 66 (54.1) 8 (8.6) 7 (15.6)
50–59 42 (34.4) 25 (26.9) 17 (37.8)
> 60 14 (11.5) 60 (64.5) 21 (46.7)
Race and ethnicity
Caucasian 107 (87.7) 86 (97.7) 43 (95.6)
Asian 8 (6.6) 0 (0) 0 (0)
Other 7 (5.7) 2 (2.3) 2 (4.4)
Smoking
Pack/day smoked (cigarettes, cigar or pipe)
Non-smoker 86 (70.5) 14 (15.1) 12 (26.7)
Ex-smoker 7 (5.8) 40 (43.0) 23 (51.1)
1 to 19 17 (13.9) 27 (29.0) 8 (17.8)
> 20 6 (4.9) 6 (6.5) 2 (4.4)
Unknown 6 (4.9) 1 (1.1) 0 (0)
Drinking
No. Of years drank >15 drinks per week
Non-drinker 9 (7.4) 2 (2.3) 5 (11.1)
Ex-drinker 0 (0) 3 (3.4) 4 (8.9)
1 to 14 31 (25.4) 6 (6.8) 15 (33.3)
> 15 3 (2.4) 11 (12.5) 7 (15.6)
Unknown 79 (64.8) 66 (75.0) 14 (31.1)
Tumour characteristics
AJCC TNM stage
Stage 0 0 (0) 0 (0)
Stage I 17 (19.3) 2 (4.4)
Stage II 15 (17.0) 2 (4.4)
Stage III 10 (11.4) 7 (15.6)
Stage IVa 23 (26.1) 26 (57.8)
Stage IVb 2 (2.3) 4 (8.9)
Stage IVc 1 (1.1) 0 (0)
Unknown 20 (22.7) 4 (8.9)
Tumour anatomic site
Table 1 The demographic characteristics of the study cohort
(n = 255) (Continued)
Oral cavity 67 (76.1) 4 (8.9)
Oropharynx 11 (12.5) 39 (86.7)
Hypopharynx 2 (2.3) 0 (0)
Larynx 6 (6.8) 1 (2.2)
Neck 2 (2.3) 1 (2.2)
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Methylation-specific PCR assays
The MSP primer pairs (RASSF1a, p16INK4a, TIMP3) used
in this study has been extensively validated in other
studies, except for MED15/PCQAP [6, 25]. MED15/
PCQAP novel CpG sites were identified by our group
and we have previously confirmed the specificity of
amplicons using the MSP primer pairs and we have also
verified the PCR amplicon sequence (Additional file 1:
Figure S1) [25]. The primer specificities for RASSF1a
and p16INK4a were confirmed by Divine et al., 2006 using
the denaturing high performance liquid chromatography
(DHPLC) [6, 33]. Similarly, TIMP3 MSP primer pairs
was initially used in a MethyLight assay by Eads et al. in
2001 and later modified by Righini et al. to be compat-
ible with a MSP assay [34, 35].
To determine the specificity of the MSP primers, all
MSP primers (both methylation and unmethylation)
were tested using bisulfite unconverted DNA samples
and was found not to amplify. This proves the specificity
of the primer pairs used in this study. Unmethylation
PCRs were used as a normaliser for methylation PCRs.
Samples without unmethylation bands were either dis-
carded from the analysis or repeated. Bisulfite-treated
methylated HeLa cell line DNA (Cat. No.4007s, New
England Biolabs, Ipswich, Massachusetts, USA) was used
as a positive control while DNase/RNase-free distilled
water (blank) was used as a negative control for the
MSP assays.
The quantitative nature and efficiency of conventional
MSP was established by using bisulfite-treated methyl-
ated HeLa cells at varying amounts. In brief, HeLa cells
were spiked in oral adenosquamous carcinoma cell line,
(CAL27) in a six-point serial dilution format to generate
a standard curve using the ratio of methylation to
unmethylation PCR reactions (Fig. 1) [36]. Our results
clearly demonstrate that the conventional MSP is a reli-
able way to relatively quantify methylation levels (MSP
efficiencies of >0.8) (Fig. 1).
RASSF1α and p16INK4a were amplified using nested
MSP. Nested MSP primer sets for both stage-1 (nested,
methylation-insensitive stage) and 2 (methylation-sensi-
tive stage) are presented in Table 2 [6]. Briefly, stage-1
PCR amplification for RASSF1α and p16INK4a was car-
ried out using 1 μM of the appropriate nested primer
sets, 6.25 μL of EmeraldAmp® MAX HS PCR Master
Mix (TaKaRa Bio Inc., Otsu, Shiga, Japan) and 1.25 ng
and 20 ng of DNA template respectively. The total reac-
tion volume of 12.5 μL was subjected to PCR amplifica-
tion using the following conditions: initial denaturing
stage at 94 °C for two minutes, followed by 30 cycles of
Fig. 1 A six-point standard curve spiking of positive cell line, HeLa in oral adenosquamous cell carcinoma, CAL27 of a RASSF1α, b p16INK4a, c
TIMP3, d PCQAP 5′ and e PCQAP 3′
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15 s at 94 °C, 15 s at 60 °C and 15 s at 72 °C. In stage-2,
two corresponding sets of methylated and unmethylated
primers for each gene were used. The amplification cyc-
ling conditions included: initial denaturing stage at 94 °C
for 2 min, followed by 5 cycles of 15 s at 94 °C, 15 s at
62 °C and 15 s at 72 °C with three repeats of decreasing
annealing temperature (64, 62 and 60 °C in that order)
before extension stage at 72 °C for 5 min. Stage-2 PCRs
used 1 μL of stage-1 product as DNA template.
For TIMP3, unique methylated and unmethylated pri-
mer sets for each gene was used to target their corre-
sponding CpG-methylation sites (Table 2) [34]. The PCR
reaction consisted of 5 μL of EmeraldAmp® MAX HS
PCR Master Mix and 0.8 μM of their respective primer
sets, in 10 μL final reaction volume. Total DNA template
ratio of 20:1 was used for the methylated reaction and
unmethylated reaction respectively. The PCR amplifica-
tion consisted of initial denaturing stage at 95 °C for
5 min, followed by 40 cycles of 15 s at 94 °C, 15 s at 54 °
C and 15 s at 72 °C before summing up with elongation
stage at 72 °C for 4 min.
Similar to TIMP3, PCQAP (Table 2) also required two
separate setup conditions for the methylated and
unmethylated reactions under the same cycling condition.
Both methylated and unmethylatd reactions consisted of
6.25 μL of EmeraldAmp® MAX HS PCR Master Mix and
1 μM of their respective primer sets. In terms of DNA
template concentrations, ratio of 25:1 was used for the
methylated reactions and unmethylated reactions respect-
ively. The PCR amplification consisted of initial denatur-
ing stage at 95 °C for 3 min, followed by 35 cycles of 30 s
at 94 °C, 30 s at 62.5 °C and 1 min at 72 °C before sum-
ming up with elongation stage at 72 °C for 5 min. PCQAP
MSP reactions required an addition of 5 % DMSO and
0.1 μg/mL BSA to minimise the presence of unspecific
bands caused by secondary DNA structures [25].
Table 2 Methylation specific PCR primer sequences
Gene Nucleotide sequence PCR product size,
base pair (bp)
Methylation-independent primer sequences (nested)
RASSF1α Forward: 5′-GGAGGGAAGGAAGGGTAAGG-3′ 260
Reverse: 5′-CAACTCAATAAACTCAAACTCCC-3′
p16INK4a Forward: 5′-GAGGAAGAAAGAGGAGGGGTTG-3′ 274
Reverse: 5′-ACAAACCCTCTACCCACCTAAATC-3′
Methylated allele-specific primer sequences
RASSF1α Forward: 5′-GGGGGTTTTGCGAGAGCGC-3′ 203
Reverse: 5′-CCCGATTAAACCCGTACTTCG-3′
p16INK4a Forward: 5′-GAGGGTGGGGCGGATCGC-3′ 143
Reverse: 5′-GACCCCGAACCGCGACCG-3′
TIMP3 Forward: 5′-GCGTCGGAGGTTAAGGTTGTT-3′ 116
Reverse: 5′-CTCTCCAAAATTACCGTACGCG-3′
PCQAP 5′ Forward: 5′-GTTTTGTGATTGAGGYGGCGGC -3′ 167
Reverse: 5′-AAAAATCCCACAATCCAACCC -3′
PCQAP 3′ Forward: 5′-GATATGGGTGGTGGGAGTTGGG -3′ 172
Reverse: 5′- AATCAGACCCTAACCTCGCCCG -3′
Unmethylated allele-specific primer sequences
RASSF1α Forward: 5′-GGTTTTGTGAGAGTGTGTTTAG-3′ 172
Reverse: 5′-ACACTAACAAACACAAACCAAAC-3′
p16INK4a Forward: 5′-TTATTAGAGGGTGGGGTGGATTGT-3′ 145
Reverse: 5′-CAACCCCAAACCACAACCATAA-3′
TIMP3 Forward: 5′-TGTGTTGGAGGTTAAGGTTGTTTT-3′ 122
Reverse: 5′-ACTCTCCAAAATTACCATACACACC-3′
PCQAP 5′ Forward: 5′-GTTTTGTGATTGAGGYGGTGGT -3′ 167
Reverse: 5′-AAAAATCCCACAATCCAACCC -3′
PCQAP 3′ Forward: 5′- TGATTAATTTAGATTGGGTTTAGAGAA -3′ 158
Reverse: 5′- CCAACTCCAAATCCCCTCTCTAT -3′
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Gel electrophoresis and densitometry analysis
MSP analysis was carried out by running 5 μL PCR
amplicon products on 2 % agarose gel. The gels were
scanned on Fusion SL (Vilber Lourmat, Marne la Vallee,
France) and visualized using ImageJ software (National
Institutes of Health, Bethesda, Maryland, USA). In order
to quantify the ratio between methylated and unmethy-
lated bands, samples with saturated bands were re-run
with a lower concentration ratio of DNA template for
both methylated and unmethylated PCRs.
The methylated and unmethylated band intensities
were quantified using ImageJ software and the ratio
between methylated to unmethylated was calculated
for each sample using Microsoft Excel (Microsoft
Corporation, Redmond, Washington, USA). A stand-
ard rectangular-frame was estimated according to the
size of the smallest band in a given gel. Consequently,
the same rectangular-frame was used to measure the
intensity of each band within the same gel to provide
consistency. The measurement was set at integrated
density to calculate the intensity value of the band
based on the amount of amplicon present. All quanti-
fications were carried out by two independent re-
searchers to minimise observational errors.
Statistical analysis
The statistical analysis was carried out by using Graph-
Pad Prism (GraphPad Software, Inc, San Diego, Califor-
nia, USA) and R (R.D.C. Team, Vienna, Austria). The
methylation levels were not normally distributed and
therefore a non-parametric test (Mann-Whitney U test)
was used when comparing the data generated using
normal healthy controls with HPV-negative and HPV-
positive HNSCC patients respectively. In addition,
Spearman’s rank correlation test was used to determine
the correlation between patients’ age and methylation
level given that age is a continuous variable.
The overarching aim of this study is to evaluate the
diagnostic potential of the combined five tumour-
suppressor genes in a panel and as such, the sensitivity
and specificity were estimated. For this purpose, the ‘Epi’
package was used in R [37]. The patient status is used as
the outcome variable and the methylation level for each
gene is used as the explanatory variables in a multivari-
able logistic regression (Carstensen’s multivariate ROC
curve). Predicted scores are then produced for each pa-
tient using the estimated regression model and different
cut-off values of this predicted score are used for classi-
fying samples into patients or controls. A known issue in
this case is that the predicted classification of the sam-
ples is optimal since the same sample that has been used
for creating the predicting model and for validating it.
One good solution to address this type of issue is known
as cross validation, the idea of which that proportion of
the sample is used for creating the predictive model, and
the remaining samples are used for validating the model
[38–40]. In this case, a version of five-fold cross-
validation was used. This is crucial to see how well the
panel translates into clinical diagnosis. To make best use
of our data, a bootstrap procedure was also incorporated
[38–40]. With this statistical method, random samples
are created by sampling with replacement from the ori-
ginal sample. The advantage of this technique is that the
confidence intervals produced are more realistic com-
pared to the parametric, asymptotic ones. Furthermore,
this was done in a stratified manner; classifying on pa-
tient status in order to retained the original samples’
characteristics. Therefore, this procedure could be called
a stratified bootstrap ROC with cross-validation. A cus-
tom written code was used to implement this in R using
the above function from R. The program was ultimately
run for 5000 times to include all possible combinations
of predictive model available. The maximum sum of sen-
sitivity and specificity was used to determine the best
cut-off point for the panel.
TCGA data portal
To investigate the tumour methylation status of the five
genes, we downloaded The Cancer Genome Atlas
(TCGA) data for HNSCC tumours and normal tissues
(https://tcga-data.nci.nih.gov/tcga/). HPV status annota-
tion was available for 268 tumours profiled by Tang et
al., (DOI:10.1038/ncomms3513; Additional file 2: Table
S1) [41]. Tumours were grouped as HPV-positive
HNSCC (n = 44), HPV-negative HNSCC (n = 223), or
normal tissue samples (n = 50). Our approach was to se-
lect probes that overlapped within the CpG sites flanking
our primer pairs used in our MSP assays (Additional file
3: Figure S2). Probes for RASSF1α, TIMP3 and PCQAP
were extracted and the DNA methylation values for
these three groups were plotted in R. However, there
were no probes that overlapped or positioned adjacent
to the CpG methylation sites interrogated by our
p16INK4a MSP assays. As such, we were unable to
present TCGA data for p16INK4a.
Results
Population characteristics
The mean age for normal healthy controls was 50 years
(SD: 8.4 years), and consisted of 44.3 % men and 55.7 %
women (Table 1). The mean age for HNSCC patients
was 64 years (SD: 12.2 years), and consisted of 82.0 %
men and 18.0 % women (Table 1). Cancer sites were
mostly of oropharyngeal and oral cavity (53.4 and 37.6 %
respectively) while laryngeal and neck cancers made up
about 7.5 % of cases with only 1.5 % of cases were hypo-
pharyngeal. In addition, 27.1 % of cases were stage I and
II, whilst 54.9 % of cases were stages III and IV (Table 1).
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Within the HNSCC patient cohort, 4.5 % of patients
were classified as current smokers, or having quit within
the past 12 months, while 47.4 % were former smokers
(quit more than one year ago) and 19.5 % have never
smoked (Table 1). Although we do not have all the pa-
tient information regarding alcohol consumption, most
of the recruited patients were alcohol users (71 %)
(Table 1).
HPV-positive HNSCC patients (n = 45) were on average
younger than HPV-negative HNSCC patients (n = 88)
(mean age: 60 years, SD: 10.4 years, for HPV-positive
HNSCC patients and mean age: 66 years, SD: 12.6 years
for HPV-negative HNSCC patients, p < 0.0001) (Table 1).
There were significantly more men than women patients
by HPV status (93.3 % men in HPV-positive HNSCC
cohort; 76.1 % men in HPV-negative HNSCC cohort, p <
0.0001) (Table 1). The majority of HPV-negative HNSCC
patients had cancers within the oral cavity (76.1 %)
whereas the majority of HPV-positive HNSCC patients
had cancers in the oropharynx (86.7 %) (Table 1). Com-
pared to HPV-negative HNSCC patients, HPV-positive
HNSCC patients were mostly diagnosed with stage IV tu-
mours (29.5 and 66.7 % respectively) (Table 1). This is pri-
marily due to the higher frequency of patients with N2
neck disease that is commonly seen in HPV-positive
HNSCC [42]. Most HPV-negative and HPV-positive
HNSCC patients were current (31.8 and 22.2 % respect-
ively) and former (45.5 and 51.1 % respectively) smokers
(Table 1).
Evaluate the stability of bisulfite-converted DNA
To achieve the uniformity across all of the MSP assays
carried out at different times, the stability of the bisulfite
converted DNA was tested. MSPs were carried out using
converted DNA on five methylated DNA tumour-
suppressor genes on a weekly basis for three months. Our
densitometry results showed consistency (coefficient of
variation, CV of <5 %) across the three month time period
when bisulfite converted DNA templates were stored at
4 °C, demonstrating the stability of the MSP reactions
(data not shown). All of the MSP data used in this paper
were generated within three months’ time period.
Evaluate the specificity of MSP primers
MSP primers for individual tumour-suppressor gene were
investigated using bisulfite unconverted DNA. When
using bisulphite unconverted DNA, we were unable to
detect any PCR amplifications further confirming the
specificity of our MSP primers. In addition, as stated
above, all of the five DNA methylation tumour genes
investigated in this study have been extensively validated
previously [6, 25, 33–35].
Evaluate the reproducibility of MSP
Inter and intra-assay variations were carried out using
randomised samples for all five methylated DNA
tumour-suppressor genes. The inter- and intra-assay
CVs fell within the range of 10 to 20 % for all of the
studied genes. The limit of detection for our MSP assays
were: 1.25 ng/μL of bisulfite-converted DNA for
RASSF1α, 20 ng/μL of bisulfite-converted DNA for
p16INK4a and TIMP3 and 25 ng/μL of bisulfite-converted
DNA for PCQAP respectively.
Five individual tumour-suppressor gene DNA methylation
levels in saliva collected from HNSCC patients and normal
healthy controls
The five individual tumour-suppressor gene DNA
methylation levels showed no significant association with
age. DNA methylation levels were relatively higher in
saliva collected from HPV-negative patients whilst lower
in saliva collected from HPV-positive HNSCC patients
compared with normal healthy controls (Additional file
4: Table S2). RASSF1α, PCQAP 5′ and PCQAP 3′ were
significantly (p < 0.0001, p < 0.0001 and p < 0.005 re-
spectively) hypermethylated in saliva collected from
HPV-negative HNSCC patients whilst p16INK4a, PCQAP
5′and PCQAP 3′ were significantly (p < 0.005, p < 0.05
and p < 0.005 respectively) hypomethylated in the saliva
collected from HPV-positive HNSCC patients compared
with normal healthy controls (Fig. 2). Table 3 summa-
rises the predictive accuracies for the five individual
tumour-suppressor genes.
Differential diagnosis of HPV-negative and HPV-positive
HNSCC patients using the five tumour-suppressor gene
panel
The Carstensen’s multivariate receiving operating char-
acteristic, ROC curve offers the best case scenario of the
panel’s performance based on the original samples that
were used in building the model (Fig. 3). With this ap-
proach, this panel performed extremely well with the
area under curve (AUC) of 0.86, sensitivity of 71 % and
specificity of 80 % when discriminating HPV-negative
HNSCC patients from normal healthy controls; and
AUC of 0.80, sensitivity of 80 % and specificity of 74 %
when comparing HPV-positive HNSCC patients with
normal healthy controls (Fig. 3). The data was then
processed using five-fold cross-validation and bootstrap
to determine the performance of this panel in a ‘most
likely scenario’ with the intention of clinical translation.
The results obtained suggest that the panel is more ap-
propriate for HPV-negative HNSCC diagnosis as the
sensitivity and specificity were least influenced by the
enforced probability (Table 4).
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Fig. 2 Overall DNA methylation profiles in the three groups. Whisker-box plot for the methylation signatures of a RASSF1α, b p16INK4a, c TIMP3, d
PCQAP 5′ and e PCQAP 3′ in the saliva of normal healthy controls (n = 122), HPV-positive (n = 45) and HPV-negative (n = 88) HNSCC patients with
inter-quartile range and median shown using non-parametric Mann-Whitney’s U-test. Significant difference between each categories were marked
with * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001, respectively
Table 3 The clinical performance for the individual tumour suppressor genes
HPV-status Biomarker/Predictor Sensitivity (%) Specificity (%) PPV (%) NPV (%) AUC p-value
HPV-negative RASSF1a 41 92 66 80 0.69 <0.0001*
p16INK4a 47 69 62 55 0.55 0.12
TIMP3 37 82 62 62 0.56 0.10
PCQAP 5′ 82 46 76 55 0.70 <0.0001*
PCQAP 3′ 34 85 62 64 0.59 <0.005*
HPV-positive RASSF1a 68 40 75 32 0.53 0.77
p16INK4a 73 67 86 48 0.69 <0.005*
TIMP3 27 92 75 58 0.51 0.94
PCQAP 5′ 81 44 84 38 0.62 <0.05*
PCQAP 3′ 76 63 86 46 0.68 <0.005*
The summary of predictive accuracy of the five individual DNA methylation genes in saliva collected from normal healthy controls and HPV-negative and HPV-
positive HNSCC patients using Mann-Whitney’s U-test and receiver operative characteristic curve. Significant difference between each category was marked with *
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TCGA data for HNSCC tumour and normal tissues
The criteria for probes selection for individual tumour-
suppressor gene are based on whether the probes are sit-
uated in the region of methylated cites amplified by
MSPs. Four of our DNA methylation loci could be found
in the TCGA data base and these were RASSF1α, TIMP3,
PCQAP 5′ and PCQAP 3′. We were unable to locate a
corresponding probe relevant to p16INK4a in the TCGA
data base (Additional file 5: Figure S3). While the
methylation data for RASSF1α from TCGA correlated
with the DNA methylation levels in saliva collected from
HPV-positive HNSCC patients, the overall methylation
status of TIMP3 and PCQAP did not vary significantly
in tumour samples compared to salivary DNA methyla-
tion levels. This may be due to the differences in ana-
tomical sites where tumours have been analysed in the
TCGA data.
Discussion
Differential DNA methylation in tumour-suppressor
genes is a frequent event during human neoplasms [43].
DNA methylation plays a significant role in head and
neck carcinogenesis [26, 27, 44]. In this study, we de-
scribe a five DNA methylation panel (RASSF1α, p16INK4a,
TIMP3, PCQAP 5′ and PCQAP 3′) that can discriminate
HPV-negative and HPV-positive HNSCC patients from
normal healthy control smokers and non-smokers. Signifi-
cantly higher DNA methylation levels were observed in
saliva collected from HPV-negative HNSCC patients com-
pared with normal healthy controls. In contrast, a signifi-
cant reduction in DNA methylation was detected in saliva
collected from HPV-positive HNSCC patients compared
with HPV-negative HNSCC patients. In general, DNA
methylation levels were similar or lower in the saliva
collected from HPV-positive HNSCC patients com-
pared with the saliva collected from normal healthy
controls. Our data corroborates previously published
findings that HPV integration reduces global methyla-
tion levels [45, 46].
DNA methylation in tumour-suppressor genes is an
early event in tumorigenesis; hence, it is likely to repre-
sent an ideal biomarker to evaluate early-stage tumour
activities [43]. Based on the current literature, all four of
Fig. 3 Performance of the panel in detecting HPV-negative and positive HNSCC. Carstensen’s multivariate receiver-operating characteristics curve
when all of the five salivary methylation genes are combined, comparing normal healthy controls (n = 122) with HPV-negative HNSCC patients
(n = 88) (blue bar); and normal healthy controls (n = 122) with HPV-positive (n = 45) HNSCC patients (red bar) respectively
Table 4 Validation test of the five tumour suppressor genes as
a panel
Mean Bootstrap SD 2.50 % 97.50 % Pval
(a) Diagnostic potential of the panel for HPV-negative HNSCC
Sensitivity 0.67 0.14 0.38 0.94 0.16
Specificity 0.83 0.13 0.50 1.00 0.04
PPV 0.79 0.12 0.55 1.00 0.003
NPV 0.77 0.08 0.63 0.94 0
(b) Diagnostic potential of the panel for HPV-positive HNSCC
Sensitivity 0.76 0.17 0.33 1.00 0.15
Specificity 0.67 0.14 0.35 0.90 0.16
PPV 0.53 0.12 0.33 0.78 0.74
NPV 0.87 0.08 0.70 1.00 0
(c) Diagnostic potential of the panel for HNSCC irrespective of HPV
status
Sensitivity 0.59 0.14 0.33 0.88 0.46
Specificity 0.78 0.15 0.45 1.00 0.07
PPV 0.78 0.10 0.59 1.00 0
NPV 0.62 0.08 0.50 0.8 0.04
Four main quantities commonly assessed in a diagnostic test (namely;
sensitivity, specificity and positive and negative predictive value) are
calculated for this panel. The table was formulated into three grouping for
three different comparisons: (a) HPV-negative HNSCC patients against normal
healthy controls, (b) HPV-positive HNSCC patients against normal healthy con-
trols and lastly (c) all HNSCC patients (regardless of HPV status) against normal
healthy controls. The results shown are the mean, standard deviation, 95 %
confidence interval and the p value (assessed from the null hypothesis value
of 0.5) for 5000 bootstrap samples, using five-fold cross-validation
Lim et al. BMC Cancer  (2016) 16:749 Page 9 of 12
the genes analysed in our study have vital roles in regu-
lating cell proliferation either directly or indirectly [47–
56]. Down regulation of RASSF1α was found in many
cancer types including head and neck, lung, breast, pros-
tate, ovarian, gastric, bladder and colorectal [57–64].
Promoter regions of RASSF1α were found to be hyper-
methylated in tumour tissues compared to normal tis-
sues [57–63]. In addition, numerous studies have shown
that the DNA methylation levels in saliva for RASSF1α
mirrors actual tumour activities [6, 26, 34, 65].
p16INK4a protein expression in tumour tissue samples
is a current gold stand to determine HPV status in
HNSCC patients [32, 66]. This is due to the fact that
while the promoter region of p16INK4a is hypermethy-
lated in most cancer types, it was found to be signifi-
cantly hypomethylated (elevated protein expression) in
HPV-positive HNSCC tumour tissues as well as in
saliva samples [67]. During HPV-16 integration, HPV-
16 E7 binds to pRb and releases E2F which then re-
sult in rapid cellular proliferation, resulting in higher
expression of p16INK4a [68]. A significant reduction in
p16INK4a DNA methylation was observed in saliva
from HPV-positive HNSCC patients compared with
saliva from normal healthy controls, further confirm-
ing the diagnostic utility of p16INK4a protein expres-
sion in tumour tissues for determining HPV status. In
addition, our findings also corroborated with previous
literature, further enforcing the distinct biological and
clinical features between HPV-positive and HPV-
negative HNSCC patients [5, 7, 69].
TIMP3 DNA methylation levels were higher in saliva
collected from HPV-negative HNSCC patients compared
to normal healthy controls. DNA promoter hypermethy-
lation of TIMP3 has shown to be strongly associated
with HNSCC pathogenesis [70–72]. According to recent
publications, DNA methylation of TIMP3 is a robust
biomarker, which can also predict HNSCC recurrences
[34, 70–73]. In addition, the TIMP3 methylation levels
in tumour tissues were able to predict the formation of
secondary tumours [73].
While RASSF1α, p16INK4a and TIMP3 have been
extensively studied as useful biomarkers to detect
HNSCC, PCQAP/MED15 has been identified by our
group [25]. In this study, we were able to demon-
strate unequivocally that the salivary DNA methyla-
tion levels of PCQAP/MED15 could discriminate
between normal healthy controls and HPV-negative
and HPV-positive HNSCC patients. PCQAP/MED15
encodes for a protein complex member of the tran-
scriptional co-activator mediator family, specifically
the RNA polymerase II transcriptional subunit 15
[51]. It is responsible for the transcriptional regula-
tion of ligand-activated proteins such as the trans-
forming growth factor betas (TGFβs) [51]. TGFβs
play a role in cellular regulation, proliferation and
differentiation [51]. As such, PCQAP/MED15 may
have an important role as a tumour-suppressor gene
[51]. According to PubMeth database (Ghent Univer-
sity, Ghent, Kortrijk, Belgium), PCQAP/MED15 is
hypermethylated in over 66 % of oesophageal and
40 % of prostate cancers. This gene contains two an-
notated CpG islands, one at the main promoter re-
gion and another overlapping with the 14th exon
(Additional file 3: Figure S2).
Standard MSP is often regarded as a qualitative
analysis; it is also not informative when determining
the percentage of methylation levels [74]. However, to
quantify methylation bands, we used MSP coupled
with densitometry software such as ImageJ. We have
also made sure that the band intensities were not sat-
urated and that all of the MSPs were in the linear
range of the calibration standard. Based on the re-
sults, the MSP assay for the five individual tumour-
suppressor genes has been optimised to operate in a
linear range (R2 > 0.8). In order to minimise inter-
assay variation, two independent researchers quanti-
fied the bands and an average value was taken when
the results deviated >10 %. The CV of our assays fell
within the range of acceptable precision and repeat-
ability, demonstrating that the results are reliable. In
addition, the efficiency of MSP was also investigated
to address nested-MSP bias.
Conclusion
The differential DNA methylation in tumour-
suppressor genes can potentially be used in identify-
ing early-stage HPV-negative HNSCC patients as well
as to classify their HPV status accordingly. This indi-
cates that not only can this panel recognize but also
categorize patients based on their salivary DNA
methylation signature profiles. We’ve also used two
advanced statistical methods to demonstrate the clin-
ical relevance of this panel. Our panel was subjected
to a five-fold cross-validation and bootstrap statistical
analyses and was able to detect HPV-negative HNSCC
with high sensitivity and specificity. This is a great
clinical end point as it would mean that testing a sin-
gle saliva sample with a simple DNA methylation test;
one would be able to accurately discern three clinical
outcomes for a patient in a non-invasive fashion. Fur-
thermore, since the DNA is isolated from saliva,
tumour-suppressor methylation signature changes are
likely to have originated from tumour cells. In the fu-
ture, randomised, multi-site and double-blinded stud-
ies will be a highly-informative prelude to clinical
implementation of this panel to detect and discrimi-
nates HPV-positive and HPV-negative HNSCC.
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